search
Back to results

Fresh Versus Frozen Stool for Fecal Transplant in Children

Primary Purpose

Clostridium Difficile

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Transplant uses frozen anonymous stool
Transplant uses fresh familial stool
Sponsored by
Mayo Clinic
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Clostridium Difficile

Eligibility Criteria

1 Year - 18 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Eligible children between aged 1 and 18 years must have had Clostridium difficile infection that has not been eradicated despite at least two courses of antibiotics ( either metronidazole or vancomycin).

Inclusion criteria:

  • Age 1-18 years
  • Diarrhea
  • Positive Clostridium difficile infection using stool toxin testing
  • Diarrhea that has improved on antibiotics but recurs when antibiotics are stopped.
  • Willingness to undergo Fecal Microbial Transplant using frozen stool from anonymous screened donors.

Exclusion Criteria:

  • Age under 1 or over 18
  • No diarrhea

Sites / Locations

  • Mayo Clinic in Rochester

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Transplant uses fresh familial stool

Transplant uses frozen anonymous stool

Arm Description

Undergoes Fecal Microbial Transplant using fresh stool from a screened family member Followed up and assessed for eradication of Clostridium difficile Quality of life assessed Stool assessed for inflammation and microbiome

Undergoes Fecal Microbial Transplant using stool collected from screened anonymous donor that has been frozen until time of Fecal Microbial Transplant Followed up and assessed for eradication of Clostridium difficile Quality of life assessed Stool assessed for inflammation and microbiome

Outcomes

Primary Outcome Measures

Clostridium difficile (CD) Eradication; percentage of patients with negative CD toxin in stool following Fecal Microbiota Transplant
Will analyze stool sample collected 4 weeks after fecal microbiota transplant (FMT) for presence or absence of Clostridium difficile toxin. In addition, will note whether presenting symptoms improved or not after FMT.

Secondary Outcome Measures

Changes in quality of life questionnaire scores after Fecal Microbiota Transplant
Will assess quality of life using standardized Child health Questionnaire which provides a raw score of 0-100. Investigators will compare scores of all patients before Fecal Transplant and 12 weeks after in order to mark the impact of procedure outcome on children's physical and psychological health
percentage of patients with stool Calprotectin levels exceeding 50 mcg/g after Fecal Microbiota Transplant
Will assess fecal Calprotectin levels in stools prior to fecal transplant and 4 weeks after
percentage of patients with positive Lactoferrin inflammatory marker in stools after Fecal Microbiota Transplant
Analyze stool samples for presence or absence Lactoferrin before Fecal transplant and 4 weeks after

Full Information

First Posted
April 6, 2015
Last Updated
March 4, 2019
Sponsor
Mayo Clinic
search

1. Study Identification

Unique Protocol Identification Number
NCT02423967
Brief Title
Fresh Versus Frozen Stool for Fecal Transplant in Children
Official Title
A Comparison of Efficacy of Fresh Versus Frozen Donor Stool for Fecal Microbial Transplant in Children With Recurrent Clostridium Difficile Infections
Study Type
Interventional

2. Study Status

Record Verification Date
March 2019
Overall Recruitment Status
Completed
Study Start Date
April 2015 (undefined)
Primary Completion Date
March 4, 2019 (Actual)
Study Completion Date
March 4, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Mayo Clinic

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The primary goal of this study will be to assess whether stool collected and frozen from anonymous screened unrelated donors can be as effective as stool freshly collected from recipient's parents when used in Fecal Microbial Transplant for the eradication of recurrent Clostridium difficile infections in children. In the current protocols, which are more than 90% effective, each child who is receiving a fecal transplant has to provide their own donor stool, usually from a parent or close relative. This requires considerable screening costs for each case and is logistically complicated as the donor must be present and must stool just prior to the transplant. The investigators hope to show that a small number of healthy donors can provide stool samples which can be frozen and banked and then thawed for use in numerous patients. The primary goal is to show that Clostridium difficile will be eradicated as effectively (Greater than 90% success) when using the stool from the frozen donors. The study will also evaluate the inflammatory response and intestinal microbiome in young children aged 1-3 years with Clostridium difficile infections to better predict which ones will respond to fecal transplantation and which ones have incidental infections. For this question the investigators will gather stool samples to check for lactoferrin, calprotectin, and alpha1antitrypsin, and 16s ribosomal RNA analysis in children before and after the fecal transplants. The goal is to see if there is an intestinal microbiome that predisposes some children to getting sick from Clostridium difficile versus just having it incidentally.
Detailed Description
The study is designed to enroll forty children aged 1-18 with recurrent Clostridium difficile Infection (CDI). Recurrent CDI is defined as an infection that persists after three rounds of appropriate antibiotics. Enrollees will be randomly assigned to receive Fecal Microbial Transplant using stool from either a screened relative as per current protocols versus using frozen stool that has been collected from healthy volunteers. Primary outcome will be the eradication of the Clostridium difficile as defined by elimination of diarrhea with a negative Clostridium difficile toxin stool test. Secondary outcomes will include a measure of quality of life pre and post Fecal Microbial Transplant using a validated quality of life survey instrument, the Health Act Child Health Questionnaire. The investigators will also assess for inflammation in the stool using lactoferrin and calprotectin and evaluate the stool microbiome in recipients pre and post transplant using sequencing to look for any pattern that predicts successful eradication.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Clostridium Difficile

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
28 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Transplant uses fresh familial stool
Arm Type
Active Comparator
Arm Description
Undergoes Fecal Microbial Transplant using fresh stool from a screened family member Followed up and assessed for eradication of Clostridium difficile Quality of life assessed Stool assessed for inflammation and microbiome
Arm Title
Transplant uses frozen anonymous stool
Arm Type
Experimental
Arm Description
Undergoes Fecal Microbial Transplant using stool collected from screened anonymous donor that has been frozen until time of Fecal Microbial Transplant Followed up and assessed for eradication of Clostridium difficile Quality of life assessed Stool assessed for inflammation and microbiome
Intervention Type
Biological
Intervention Name(s)
Transplant uses frozen anonymous stool
Other Intervention Name(s)
fecal microbial transplant
Intervention Description
The intervention is using frozen anonymous donor stool instead of fresh stool from family members for the fecal microbial transplant to treat recurrent CDI.
Intervention Type
Biological
Intervention Name(s)
Transplant uses fresh familial stool
Other Intervention Name(s)
fecal microbila transplant
Intervention Description
The intervention is using fresh familial donor stool for the fecal microbial transplant to treat recurrent CDI
Primary Outcome Measure Information:
Title
Clostridium difficile (CD) Eradication; percentage of patients with negative CD toxin in stool following Fecal Microbiota Transplant
Description
Will analyze stool sample collected 4 weeks after fecal microbiota transplant (FMT) for presence or absence of Clostridium difficile toxin. In addition, will note whether presenting symptoms improved or not after FMT.
Time Frame
4 weeks
Secondary Outcome Measure Information:
Title
Changes in quality of life questionnaire scores after Fecal Microbiota Transplant
Description
Will assess quality of life using standardized Child health Questionnaire which provides a raw score of 0-100. Investigators will compare scores of all patients before Fecal Transplant and 12 weeks after in order to mark the impact of procedure outcome on children's physical and psychological health
Time Frame
12 weeks
Title
percentage of patients with stool Calprotectin levels exceeding 50 mcg/g after Fecal Microbiota Transplant
Description
Will assess fecal Calprotectin levels in stools prior to fecal transplant and 4 weeks after
Time Frame
4 weeks
Title
percentage of patients with positive Lactoferrin inflammatory marker in stools after Fecal Microbiota Transplant
Description
Analyze stool samples for presence or absence Lactoferrin before Fecal transplant and 4 weeks after
Time Frame
4 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Year
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Eligible children between aged 1 and 18 years must have had Clostridium difficile infection that has not been eradicated despite at least two courses of antibiotics ( either metronidazole or vancomycin). Inclusion criteria: Age 1-18 years Diarrhea Positive Clostridium difficile infection using stool toxin testing Diarrhea that has improved on antibiotics but recurs when antibiotics are stopped. Willingness to undergo Fecal Microbial Transplant using frozen stool from anonymous screened donors. Exclusion Criteria: Age under 1 or over 18 No diarrhea
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mark Bartlett, MD
Organizational Affiliation
Mayo Clinic
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mayo Clinic in Rochester
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States

12. IPD Sharing Statement

Links:
URL
https://www.mayo.edu/research/clinical-trials
Description
Mayo Clinic Clinical Trials

Learn more about this trial

Fresh Versus Frozen Stool for Fecal Transplant in Children

We'll reach out to this number within 24 hrs